Drugs / HFA-152A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06702462 | Mar → Jun 2025 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07645248 | Sep 2026 → Feb 2027 expected | asthma | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-09-03 | Chiesi Farmaceutici S.p.A. | Regulatory Chiesi advances its Carbon Minimal Inhaler journey as European submissions for its Single Inhaler Triple Therapy (SITT) and ICS/LABA combination next-generation propellant pMDIs are validated chiesi.com ↗
Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been validated by Regulatory Agencies in Europe. |
| 2025-11-26 | Chiesi Farmaceutici S.p.A. | Results Chiesi Advanced Carbon Minimal Inhaler (CMI) Program with New Therapeutic Equivalence Data Presented at British Thoracic Society (BTS) Winter Meeting chiesi.com ↗
The findings confirm that Chiesi’s beclometasone dipropionate/formoterol fumarate product formulated with hydrofluoroalkane ( HFA) 152a , delivers comparable clinical efficacy and safety to the currently marketed formulation using HFA-134a 1 . |
| 2025-10-22 | GlaxoSmithKline | Results GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler gsk.com ↗
Data confirm that the formulation of salbutamol MDI containing an innovative low carbon propellant HFA-152a shows therapeutic equivalence and is comparable in safety to salbutamol MDI containing the current propellant, HFA-134a. |
| 2025-09-26 | Chiesi Farmaceutici S.p.A. | Results Chiesi Completes Clinical Development Program for Carbon-Minimal Pressurized Metered-Dose Inhalers (pMDIs), Paving the Way for Regulatory Submissions chiesi.com ↗
The study evaluated the long-term safety and tolerability of HFA-152a, a next-generation propellant with significantly lower global warming potential (GWP) . |
| 2024-09-03 | Chiesi Farmaceutici S.p.A. | Results Chiesi Group Unveils Innovations in Respiratory Care, Patient Insights into Decentralization of a Clinical Trial and Developments in Carbon Minimal Inhaler Project at ERS Congress 2024 chiesi.com ↗
These studies collectively provided reassuring evidence of a similar performance, safety and tolerability of the new formulations, when compared to the current one, enabling a seamless and safe transition for patients and healthcare systems while significantly reducing environmental impact. |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HFA-152A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06702462 ↗ |
| Known as | Difluoroethane | “Difluoroethane [HFA-152a]” NCT06702462 ↗ |
| Route | Inhaled | “HFA-152A propellant is administered via oral inhalation” NCT06702462 ↗ |